A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

Código QR

A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.

Guardado en:

Detalles Bibliográficos
Autores principales:	Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle, Ariel S. Wirchnianski, Robert H. Bortz, Ethan Laudermilch, J. Maximilian Fels, Amanda Mengotto, Ryan J. Malonis, George I. Georgiev, Jose A. Quiroz, Daniel Wrapp, Nianshuang Wang, Kathryn E. Dye, Jason Barnhill, John M. Dye, Jason S. McLellan, Johanna P. Daily, Jonathan R. Lai, Andrew S. Herbert, Laura M. Walker, Kartik Chandran, Rohit K. Jangra
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/679d11cbba69478ca30bdf9534e81939
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Descripción
Sumario:	The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.